Professor Harald Mischak

  • Robertson Chair in Biotechnology, Professor of Proteomics (Institute of Cardiovascular and Medical Sciences)
  • Associate (School of Life Sciences)

Research interests

Harald Mischak, holds a position as Professor for Proteomics and Systems Medicine at the University of Glasgow, and is the chief scientific officer of Mosaiques AG as well as executive director of Mosaiques diagnostics GmbH and DiaPat GmbH. With more than 180 peer reviewed manuscripts published on signaling and proteomics that have been cited over 11000 times (h-index 55), he is one of the leading experts worldwide in the field of proteome research and applied systems biology. Based on his experience on proteomics in basic research, he initiated the use of urinary proteomics and capillary electrophoresis coupled mass spectrometry for clinical application. Today he is a leading authority in clinical proteomics and biomarker identification. Among his achievement in this field are the development of guidelines for clinical proteome analysis, and the identification of proteomic biomarkers and biomarker-derived classifiers for a variety of diseases (e.g. cardiovascular disease, diabetes, chronic kidney disease, bladder and prostate cancer). Several of these are already in clinical use today. His main interest are the identification of additional biomarkers, and combining the knowledge on these with literature to establish models for molecular pathology, which would enable identification of appropriate therapeutic targets, and the implementation of “personalized medicine”.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Pilot MRI Study for the Investigation of Pathophysiology in Intracerebral Haemorrhage
    Academy of Medical Sciences
    2014 - 2015
     
  • Pilot MRI Study for the Investigation of Pathophysiology in Intracerebral Haemorrhage
    Academy of Medical Sciences
    2014 - 2015
     
  • Urine proteomics as biomarker for inflammatory arthritis
    Pfizer Global Research and Development
    2013 - 2014
     
  • Cardiovascular consequences of preeclampsia in women from the Generation Scotland: Scottish Family Health Study.
    Scottish Executive Health Department
    2012 - 2014
     
  • Proteomics and Metabolomics to Help Understand and Improve Recovery in Stroke Survivors.
    The RS Macdonald Charitable Trust
    2012 - 2013
     
  • Development of an efficient, robust MS-based platform for early detection of acute kidney injury
    Medical Research Council
    2011 - 2014
     
  • The iomarkers in Stroke Programme; Detecting, Understanding, and Predicting Outcome After Stroke (ISSF Catalyst Fund)
    Wellcome Trust
    2011 - 2014
     
  • Investigating the potential of cathepsin-L as a common therapeutic target and biomarker for coronary heart disease and African trypanosomiasis (ISSF Catalyst Fund)
    Wellcome Trust
    2011 - 2014